Navigation Links
Webcast Alert: Akcea Therapeutics Conference Call
Date:5/28/2015

CARLSBAD, Calif., May 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:

Akcea Therapeutics WebcastWhen:

Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our website listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases.  These include ISIS-APOCIIIRx, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and partial lipodystrophy; ISIS-TTRRx, a drug Isis is developing with GSK to treat patients with the polyneuropathy and cardiomyopathy forms of TTR amyloidosis; and ISIS-SMNRx, a drug Isis is developing with Biogen to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis Pharmaceuticals, Isis' business, Akcea Therapeutics, the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-APOCIIIRx, ISIS-ANGPTL3Rx, ISIS-APO(a)Rx and their follow on drugs, and the discovery, development and therapeutic potential of these antisense drugs for the treatment of lipid disorders.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2014, and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Akcea Therapeutics™ is a trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO

 


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
2. Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast
3. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on May 13, 2015
4. Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders
5. Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
6. Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015
7. HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast
8. Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT
9. Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast
10. Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
11. AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 4th, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... ... 08, 2019 , ... Dr. Ryan McNally, ND, MS, PA and Dr. Shashita ... and Medicine conference. Their presentation titled Advances in Integrative Neuropsychiatry and Functional Mental Health, ... used to promote brain health, and reduce the debilitating symptoms of a range of ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... at Western Pennsylvania & Ohio Valley Oral & Maxillofacial Surgery. This cutting-edge practice ... All-on-4® full arch dental implants to predictable jaw surgery with 3D ...
(Date:10/8/2019)... Texas (PRWEB) , ... October 08, 2019 , ... A ... be held this month in Austin, Texas. The event, featuring thought leaders, innovators and ... today. , Held from 2:00 p.m. to 5:30 p.m. CT on October ...
Breaking Medicine Technology:
(Date:10/11/2019)... ... 11, 2019 , ... Inland Detox, Inc. has just moved to a new ... views of the Temecula Valley and it’s the perfect place for long-term residential ... private rooms as well as double occupancy rooms, a 2nd home where all treatment ...
(Date:10/10/2019)... ... October 10, 2019 , ... Caring.com, a leading senior care referral service ... Worst Places for Seniors to Live. All 50 states and 302 cities in the ... and workforce development. , According to the U.S. Census Bureau , almost ...
(Date:10/8/2019)... ... October 08, 2019 , ... SoCal Adolescent Wellness announces the ... announce the expansion of our services to better serve the families in Orange County," ... last year to see the extraordinary impact this pre-intervention program has on the lives ...
(Date:10/8/2019)... West Hartford, CT (PRWEB) , ... October 08, ... ... surgeons at JawFixers in West Hartford, CT, help patients with missing teeth restore ... each year, this team of oral surgeons relies on advanced i-CAT® 3D Cone ...
(Date:10/8/2019)... ... October 08, 2019 , ... At the 13th Annual ... President Gregg Church will inform conference attendees how the 4medica Perfect Order ... with the right, clean patient data. The single platform interfaces to core lab ...
Breaking Medicine News(10 mins):